Last reviewed · How we verify
Adefovir tablets
Adefovir works by inhibiting the replication of the hepatitis B virus.
Adefovir works by inhibiting the replication of the hepatitis B virus. Used for Chronic hepatitis B, Hepatitis B virus infection.
At a glance
| Generic name | Adefovir tablets |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | HBV DNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Adefovir is a nucleotide reverse transcriptase inhibitor that interferes with the viral DNA synthesis, thereby inhibiting the replication of the hepatitis B virus. This results in a decrease in viral load and a reduction in liver inflammation.
Approved indications
- Chronic hepatitis B
- Hepatitis B virus infection
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Asthenia
Key clinical trials
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
- Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir. (PHASE4)
- Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB) (PHASE3)
- Lamivudine and Adefovir Dipivoxil Fixed Dose Combination (PHASE1)
- PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278) (PHASE3)
- A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B (PHASE3)
- A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B (PHASE3)
- A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adefovir tablets CI brief — competitive landscape report
- Adefovir tablets updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI